<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

OUR RESOURCES

FEATURED CONTENT

Have your say on life sciences investment trends

LSX, formerly Biotech and Money, is conducting the 3rd Investor Perception Survey, which tracks life science investment trends and investor sentiment. The annual survey has been designed to enable life sciences companies to better understand investor...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life sciences sector, identifying relevant investors with an active investment mandate is one of the main hurdles to securing financing, according to the LSX C-Suite Challenges in Life ...

Read More

CASE STUDY

Forendo Pharma receives €4m boost to progress women’s health programmes

Key learnings: Vesalius BioCapital III Partners invested €4 million in Finl...

Read More

Evox Therapeutics raises £35.5m Series B to advance exosome technology

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More
View More

EXPERT INSIGHT

What life sciences companies need to know about pre-approval access

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Addressing the challenges of ownership structures in life sciences

The development of new products in the life science industry is a very time...

Read More
View More

INVESTORVIEW

Investorview: Ingredients for growth in life sciences investment

Industrifonden is an evergreen venture capital fund with headquarters in St...

Read More

Investorview: Why people are key in life science investments

Since it was founded in 1996, European venture capital firm HealthCap has i...

Read More

Investorview: Plugging knowledge gaps to accelerate life science start-up development

Venture capital firm Hadean Ventures closed its first fund at the end of 20...

Read More
View More

LSX REPORT

Have your say on life sciences investment trends

LSX, formerly Biotech and Money, is conducting the 3rd Investor Perception ...

Read More

Key challenges to scaling up early-stage investment in the life sciences

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More
View More

WHITE PAPER

Infographic: C-suite challenges in life sciences 2018

In early 2017, LSX, formerly Biotech and Money, published the inaugural Inv...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

Medius Deal Watch July-August 2018

This issue of Deal Watch focuses on deal activities during the months of Ju...

Read More
View More

VIDEO

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with HemoGenyx's Vladislav Sandler

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with Inmedix’s Andrew J. Holman

Andrew J. Holman, Co-Founder and Chief Executive Officer at Inmedix, talks ...

Read More
View More

EVENT

The value potential of blockchain in healthcare: Q&A with Patientory’s Chrissa McFarlane

More than nine in 10 (91%) health executive respondents believe blockchain ...

Read More

Growing opportunities in cannabinoid-based treatments: Q&A with Casa Verde Capital's Karan Wadhera

In June 2018 it was announced that venture capital firm Casa Verde Capital,...

Read More

Realising the potential of cannabinoid-related therapies: Q&A with Artelo Biosciences’ Greg Gorgas

On 10-11 October 2018, investors, industry stakeholders, and senior executi...

Read More
View More

WEBINAR

Advanced therapies: Gaining market access in a challenging European environment

Listen to the final session in Phacilitate and LSX's (formerly known as Bio...

Read More

Overcoming commercialisation challenges in advanced therapies

Learn more about the commercialisation of advanced therapies in the on-dema...

Read More

Why whistleblowing should be a boardroom issue in life sciences

On-demand webinar now available New EU-wide whistleblowing regulations have...

Read More
View More